Clearing the Signal: Serum Prostate-Specific Antigen Trajectories After Transurethral Resection or Open Simple Prostatectomy Versus Tamsulosin–Dutasteride Therapy in Men With Benign Prostatic Enlargement and a Benign Biopsy — A Secondary Analysis of a 12-Week Prospective Cohort
Health Innovation Reports · 2026
DOI: 10.64048/hir.v2n2.003 ↗Abstract
Background and aim: Men with benign prostatic enlargement often have a serum prostate-specific antigen (PSA) above 4 ng/mL, prompting biopsy; when the biopsy is benign, the expected post-treatment PSA fall is uncertain. This study compared 12-week PSA trajectories after transurethral resection of the prostate (TURP) or open simple prostatectomy with those after tamsulosin–dutasteride therapy.Methods: This secondary analysis used an open, anonymized prospective cohort of 154 men with benign prostatic enlargement, elevated PSA and a benign biopsy from the University of Nigeria Teaching Hospital, Enugu. Total PSA was measured at baseline, 6 and 12 weeks and analysed with mixed analysis of variance, multivariable linear regression and logistic regression.Results: Among 154 men (77 medical therapy, 43 TURP, 34 open prostatectomy), median baseline PSA was 5.60, 10.00 and 15.80 ng/mL, respectively (p < .001). A significant treatment × time interaction was observed (p < .001): mean 12-week reductions were 56.4%, 77.1% and 83.6%, respectively. After adjustment for baseline PSA and clinical characteristics, TURP (β = 17.12) and open prostatectomy (β = 16.98) were associated with greater reduction than medical therapy (both p < .001; adjusted R² = 0.56). Among surgical patients, higher baseline PSA reduced the odds of PSA < 4.0 ng/mL at week 6 (adjusted OR = 0.59, p < .001), whereas 96.1% had normalized by week 12.Conclusions: Surgery produced faster and deeper PSA clearance than tamsulosin–dutasteride therapy, independent of baseline PSA. A 12-week PSA check interpreted against treatment-specific expected reductions may guide follow-up.
EUVIMED